Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area

Applied Radiation and Isotopes

Volumn 64, Issue 1, 2006, Pages 32-37

  Björke, Henrik ^a   Andersson, Karl ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affinity; Cell based; Interaction; Radioligand

Indexed keywords

CELLS; MEASUREMENT THEORY; RADIOLOGY; TUMORS;

AFFINITY MEASUREMENT; CELL-BASED; INTERACTION; LIGAND-RECEPTOR INTERACTIONS; RADIOLIGAND;

MOLECULAR STRUCTURE;

CELL SURFACE RECEPTOR; RADIOLIGAND;

ARTICLE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LABORATORY AUTOMATION; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANTIBODIES; BINDING, COMPETITIVE; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; HUMANS; IODINE RADIOISOTOPES; RADIOLIGAND ASSAY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 27644582140     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2005.06.007     Document Type: Article

References (10)

1. S.J. Culliford, P. McCauley, A.J. Sutherland, M. McCairn, J. Sutherland, J. Blackburn, and R.Z. Kozlowski A novel cell-based scintillation proximity assay for studying protein function and activity in vitro using membrane-soluble scintillants Biochem. Biophys. Res. Commun. 296 4 2002 857 863
2. R. Karlsson, and R. Ståhlberg Surface plasmon resonance detection and multispot sensing for direct monitoring of interactions involving low-molecular-weight analytes and for determination of low affinities Anal. Biochem. 228 1995 274 280
3. P. Klein, D. Mattoon, M.A. Lemmon, and J. Schlessinger A structure-based model for ligand binding and dimerization of EGF receptors Proc. Natl. Acad. Sci. USA 101 4 2004 929 934
4. Q. Li, J.B. Schachter, T.K. Harden, and R.A. Nicholas The 6H1 orphan receptor, claimed to be the p2y5 receptor, does not mediate nucleotide-promoted second messenger responses Biochem. Biophys. Res. Commun. 18;236 2 1997 455 460
5. L.K. Minor Assays to measure the activation of membrane tyrosine kinase receptors: focus on cellular methods Curr. Opin. Drug Discov. Dev. 6 5 2003 760 765
6. P.M. Smith-Jones, C. Bischof, M. Leimer, D. Gludovacz, P. Angelberger, T. Pangerl, M. Peck-Radosavljevic, G. Hamilton, K. Kaserer, A. Kofler, H. Schlangbauer-Wadl, T. Traub, and I. Virgolini DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy Endocrinology 140 11 1999 5136 5148
7. A.L. Sundberg, A. Orlova, A. Bruskin, L. Gedda, J. Carlsson, E. Blomquist, H. Lundqvist, and V. Tolmachev [(1 1 1)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent Cancer Biother. Radiopharm. 18 4 2003 643 654
8. A.L. Sundberg, Y. Almqvist, A. Orlova, E. Blomquist, H.J. Jensen, L. Gedda, V. Tolmachev, and J. Carlsson Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF Eur. J. Nucl. Med. Mol. Imag. 30 10 2003 1348 1356
9. M. Wikman, A.C. Steffen, E. Gunneriusson, V. Tolmachev, G.P. Adams, J. Carlsson, and S. Stahl Selection and characterization of HER2/neu-binding affibody ligands Protein Eng. Des. Sel. 17 5 2004 455 462
10. F. Xu, Y. Yu, X.F. Le, C. Boyer, G.B. Mills, and R.C. Bast Jr. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression Clin. Cancer Res. 5 11 1999 3653 3660